Notices of Intent to Revise and Pharmacopeial Forum-Related Notices
- <64> Probiotic Tests Notice of Intent to Revise (posted 30-Jun-2023)
- <383> Cured Silicone Elastomers for Pharmaceutical Packaging and Manufacturing Components (posted 26-Apr-2024)
- <621> Chromatography Notice of Intent to Revise (posted 06-Jan-2023)
- <621>Chromatography Notice of Intent to Revise (posted 25-Aug-2023)
- <660> Container-Glass (posted 27-Jan-2023)
- <731> Loss on Drying (posted 28-Jun-2024)
- <1079.2> Mean Kinetic Temperature in the Evaluation of Temperature Excursions During Storage and Transportation of Drug Products (posted 27-Jan-2023)
- Albuterol Inhalation Solution Notice of Intent to Revise (posted 29-Sep-2023)
- Bacillus coagulans Notice of Intent to Revise (posted 28-Apr-2023)
- Bumetanide and Bumetanide Tablets Notice of Intent to Revise (posted 27-Oct-2023)
- Cetyl Palmitate Notice of Intent to Revise (posted 23-Feb-2024)
- Changes to General Notices, Section 1 (posted 28-Feb-2024)
- Chemical Information Updates (posted 28-Apr-2023)
- Clonidine Transdermal System Notice of Intent to Revise (posted 27-Oct-2023)
- Clonidine Transdermal Systems: Removal of the Test for Organic Impurities (posted 24-Feb-2023)
- Cranberry Fruit Juice Dry Extract (posted 28-Jun-2024)
- Dapsone Tablets Notice of Intent to Revise (posted 23-Feb-2024)
- Desvenlafaxine Succinate (posted 30-Aug-2024)
- Dimethyl Fumarate Delayed-Release Capsules (posted 26-Apr-2024)
- Dutasteride and Tamsulosin Hydrochloride Tablets Notice of Intent to Revise (posted 28-Jul-2023)
- Etidronate Disodium Notice of Intent to Revise (posted 27-Oct-2023)
- Erythromycin Ethylsuccinate for Oral Suspension (posted 27-Jan-2023)
- Fosfomycin Tromethamine (posted 28-Apr-2023)
- Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets Notice of Intent to Revise (posted 29-Dec-2023)
- Gadopentetate Dimeglumine Injection Notice of Intent to Revise (posted 29-Dec-2023)
- General Chapters Affected by Omission to <1118> Monitoring Devices- Time, Temperature, and Humidity (posted 18-Apr-2023)
- General Chapters Affected by Revision to <1724> Semisolid Drug Products- Performance Tests (posted 28-Apr-2023)
- General Chapters Affected by Revisions to <1912> Measurement of Yield Stress of Semisolids (posted 28-Apr-2023)
- Glucagon for Injection Notice of Intent to Revise (posted 31-Oct-2023)
- Gramicidin Notice of Intent to Revise (posted 25-Aug-2023)
- Ipratropium Bromide (posted 28-Apr-2023)
- Lactobacillus acidophilus Notice of Intent to Revise(posted 30-Jun-2023)
- Ligilactobacillus salivarus Notice of Intent to Revise (posted 30-Jun-2023)
- Magaldrate Family of Monographs Notice of Intent to Revise (posted 28-Jul-2023)
- Magnesium Sulfate Notice of Intent to Revise (posted 31-May-2024)
- Methscopolomine Bromide Tablets Notice of Intent to Revise (posted 28-Jul-2023)
- Methylprednisolone Injectable Suspension Notice of Intent to Revise (posted 23-Feb-2024)
- Monographs Affected by Revision to <616> Bulk Density of Powders (posted 28-Apr-2023)
- Norflurane Notice of Intent to Revise (posted 10-May-2024)
- Norgestimate Notice of Intent to Revise (posted 25-Aug-2023)
- Polyethylene Glycol Notice of Intent to Revise (posted 23-Feb-2024)
- Polyethylene Glycol Castor Oil Notice of Intent to Revise (posted 13-Jun-2024, input deadline 15-Jul-2024)
- Proposal to Add Flexibility in the Selection of Suitable Packaging and Storage for Parenteral Drugs (posted 27-Jan-2023)
- Protriptyline Hydrochloride (posted 26-Apr-2024)
- Rifampin, Rifampin Capsules, Rifampin for Injection, Rifampin and Isoniazid Capsules, and Rifampin, Isoniazid, and Pyrazinamide Tablets
- Roflumilast Notice of Intent to Revise (posted 23-Feb-2024)
- Rufinamide (posted 28-Jun-2024)
- Sitagliptin Tablets Notice of Intent to Revise (posted 30-Jun-2023)
- Sodium Bicarbonate (posted 03-Apr-2023)
- Sodium Polystyrene Sulfonate Suspension (posted 26-Jul-2024)
- Starch TS Notice of Intent to Revise (posted 25-Aug-2023)
- Succinic Acid Notice of Intent to Revise (posted 12-Apr-2024)
- Sucrose Notice of Intent to Revise (posted 31-Mar-2023)
- Sucrose Notice of Intent to Revise (posted 23-Feb-2024)
- Teniposide Notice of Intent to Revise (posted 27-Oct-2023)
- Teriparatide Injection (posted 28-Jun-2024)
- Tobramycin Inhalation Solution Notice of Intent to Revise (posted 27-Oct-2023)
- Xylazine (posted 30-Aug-2024)
- Xylazine Hydrochloride (posted 30-Aug-2024)
- Xylazine Injection (posted 30-Aug-2024)
- Zinc Family of Monographs Notice of Intent to Revise (posted 25-Aug-2023)
- Zinc Sulfate Injection Notice of Intent to Revise (posted 28-Jul-2023)
